Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.43 |
| ▸ | RBBP9 | O75884 | 2/20 | 0.43 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8772481 | 0.81 | PLA2G7 (0.53) | CYP1A2CYP2D6CYP2C19PLA2G7ALDH1A1 | |
| SCHEMBL3830939 | 0.80 | MAPT (0.57) | CYP1A2CYP2D6CYP2C19PLA2G7ALDH1A1 | |
| SCHEMBL2008703 | 0.80 | PLA2G7 (0.57) | PLA2G7ALDH1A1MEN1NPC1LMNA | |
| SCHEMBL3830934 | 0.79 | PLA2G7 (0.55) | CYP1A2CYP2D6CYP2C19PLA2G7ALDH1A1 | |
| SCHEMBL1367377 | 0.79 | PLA2G7 (0.51) | CYP1A2CYP2D6CYP2C19PLA2G7ALDH1A1 | |
| Bromide SCHEMBL27504054 | 0.78 | PLA2G7 (0.56) | PLA2G7ALDH1A1MEN1NPC1LMNA | |
| SCHEMBL14419230 | 0.77 | KCNMA1 (0.60) | CYP1A2CYP2D6CYP2C19PLA2G7ALDH1A1 | |
| SCHEMBL13252870 | 0.77 | PLA2G7 (0.49) | CYP1A2CYP2D6CYP2C19PLA2G7ALDH1A1 | |
| SCHEMBL343646 | 0.76 | GCK (0.61) | CYP1A2CYP2D6CYP2C19PLA2G7ALDH1A1 | |
| SCHEMBL8492044 | 0.76 | ALDH1A1 (0.47) | CYP1A2CYP2D6CYP2C19PLA2G7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103360336-B | A kind of synthetic method of antifungus agent O | 上海三爱思试剂有限公司 | 2016-08-10 | — | — | CN | claimed |
| CN-103360336-B | A kind of synthetic method of antifungus agent O | 上海三爱思试剂有限公司 | 2016-08-10 | — | — | CN | disclosed |
| EP-2104677-B1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-12-07 | — | — | EP | disclosed |
| EP-2104677-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-09-30 | — | — | EP | disclosed |
| US-7498339-B2 | Spiropiperidine glycinamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080194610-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | US | disclosed |
| WO-2008084005-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-17 | — | — | WO | disclosed |
| US-20080171759-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171760-A1 | e.g. N-[(4-Chlorophenyl)(phenyl)methyl]-2-oxo-2-(1'H,3H-spiro[2-indane-1,4'-piperidin]-1'-yl)ethanamine; vasopressin V1a receptor antagonist; antidepressant, anxiolytic, hypotensive agent; dysmenorrhea, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
| WO-2007104696-A1 | ANTIMALARIAL AGENTS HAVING POLYAROMATIC STRUCTURE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194610-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | AVPR1A, AVPR1B, GLRA1 | CYP1A2 494/4885CYP2D6 761/4885CYP2C19 479/4885 |
| US-20080171760-A1 | e.g. N-[(4-Chlorophenyl)(phenyl)methyl]-2-oxo-2-(1'H,3H-spiro[2-indane-1,4'-piperidin]-1'-yl)ethanamine; vasopressin V1a receptor antagonist; antidepressant, anxiolytic, hypotensive agent; dysmenorrhea, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | AVPR1A, AVPR2, AVPR1B | CYP1A2 582/4885CYP2D6 912/4885CYP2C19 930/4885 |
| US-20080171759-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | AVPR1A, AVPR1B, GLRA1 | CYP1A2 494/4885CYP2D6 761/4885CYP2C19 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.